AChR CAAR T Cells for Selective Myasthenia Gravis B-Cell Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for myasthenia gravis, such as acetylcholinesterase inhibitors and immunosuppressive drugs, are not specific and effective, leading to significant side effects and complications, particularly in severe cases.
Innovation Solution
Development of a chimeric autoantibody receptor (CAAR) that targets acetylcholine receptor autoantigens, comprising an extracellular domain, transmembrane domain, and intracellular signaling domains, engineered into cells to specifically bind and kill B cells producing autoantibodies, thereby reducing neuromuscular junction damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If acetylcholinesterase inhibitors and immunosuppressive drugs are used to treat myasthenia gravis, then muscle weakness symptoms are alleviated, but significant side effects and complications occur due to lack of specificity
Solution Approach 1:
The patent segments the treatment approach by creating a chimeric autoantibody receptor that specifically targets only the pathogenic B cells producing autoantibodies against acetylcholine receptors, rather than using broad-spectrum immunosuppressive drugs that affect all immune functions. This segmentation allows selective elimination of harmful immune cells while preserving normal immune function.
Solution Approach 2:
The chimeric autoantibody receptor introduces local quality by providing site-specific targeting capability. The receptor is designed with an extracellular domain that specifically binds to autoantibodies, enabling the engineered T cells to selectively identify and destroy only the B cells producing pathogenic autoantibodies, while leaving other B cells and immune functions unaffected.
2Reliability
If broad-spectrum immunosuppressive therapy is applied, then overall immune suppression is achieved, but specificity and precision of treatment are lost
Solution Approach 1:
The chimeric autoantibody receptor acts as an intermediary that bridges the engineered T cells and the pathogenic B cells. The receptor's extracellular domain specifically recognizes and binds to autoantibodies on the B cell surface, serving as a precise mediator that enables selective targeting without affecting other immune cells. This intermediary mechanism provides both immune suppression efficacy and treatment specificity.
Solution Approach 2:
The patent applies parameter changes by modifying T cells through genetic engineering to express the chimeric autoantibody receptor. This parameter change transforms ordinary T cells into highly specific effector cells that can precisely identify and eliminate pathogenic B cells based on the presence of autoantibodies, thereby achieving both immune suppression and treatment specificity.
3Ease of operation
If conventional treatments are used, then general symptom management is achieved, but neuromuscular junction damage continues due to lack of targeted intervention
Solution Approach 1:
The patent applies preliminary action by engineering T cells in advance to express the chimeric autoantibody receptor before administering them to patients. These pre-engineered cells are ready to immediately recognize and destroy pathogenic B cells upon contact, providing targeted intervention that prevents further neuromuscular junction damage from the outset, rather than waiting for damage to occur.
Data Source
AI summary
The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-acetylcholine receptor (AChR) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells, e.g., T cells comprising the CAAR.